SCHEMBL48811

SCHEMBL48811

CCN(OC)S(=O)(=O)c1ccc(-c2sc(NC(C)=O)nc2C)cc1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 12/20 0.65
PIK3CG P48736 12/20 0.65
PIK3CA P42336 10/20 0.65
PIK3CB P42338 10/20 0.65
PI4KB Q9UBF8 8/20 0.49
PIK3C3 Q8NEB9 2/20 0.47
PIK3C2A O00443 1/20 0.47
PIK3C2B O00750 1/20 0.47
PI4KA P42356 1/20 0.47
PRKDC P78527 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48486 0.86 PIK3CG (0.69) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48445 0.85 PIK3CD (0.65) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48423 0.84 PI4KB (0.68) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48569 0.83 PIK3CG (0.75) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48588 0.80 PIK3CG (0.73) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48857 0.79 PIK3CG (1.00) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48516 0.79 PIK3CG (0.81) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48391 0.78 PIK3CG (1.00) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48810 0.77 PIK3CD (0.66) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48492 0.77 PIK3CG (0.77) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP claimed
EP-2311818-B1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug NOVARTIS AG (CH) 2013-01-16 EP disclosed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
EP-2311818-A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug Novartis AG (CH) 2011-04-20 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B PIK3CD 4/4885PIK3CG 8/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.